Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael

Showing results (1121-1130 of 1,257) with videos related to

Pageof 126
Sort By:
JAMA|April 1, 2014
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trialA Michael Lincoff, Jean-Claude Tardif, Gregory G Schwartz, et al.
International Journal of Experimental Diabesity Research|May 15, 2003
Development of type 1 diabetes in wild bank voles associated with islet autoantibodies and the novel ljungan virusBo Niklasson, Knud E Heller, Bryan Schønecker, et al.
Journal of the American College of Cardiology|July 25, 2009
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trialAbhiram Prasad, Bernard J Gersh, Michel E Bertrand, et al.
Journal of the American College of Cardiology|February 21, 2004
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trialHitinder S Gurm, A Michael Lincoff, David Lee, et al.
European Heart Journal|September 2, 2015
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trialsJacob A Udell, Marc P Bonaca, Jean-Philippe Collet, et al.
Nature Communications|October 9, 2015
Structure of Ljungan virus provides insight into genome packaging of this picornavirusLing Zhu, Xiangxi Wang, Jingshan Ren, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 18, 2012
Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experienceOlcay Aksoy, E Murat Tuzcu, Stephen G Ellis, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 28, 2020
Association of adoption of transradial access for percutaneous coronary intervention in ST elevation myocardial infarction with door-to-balloon timeChetan P Huded, Samir R Kapadia, Jad A Ballout, et al.
The American Surgeon|May 5, 2023
Effects of the COVID-19 Pandemic on the Trauma Population in a Level 1 Trauma CenterJavier A Michael, Morgan E Roberts, Andrew N Haiflich, et al.
Clinical Cardiology|August 25, 2020
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)Calvin C Sheng, Debasis Sahoo, Siddharth Dugar, et al.
Pageof 126

Showing results (1121-1130 of 1,257) with videos related to

Sort By:
Pageof 126
JAMA|April 1, 2014
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trialA Michael Lincoff, Jean-Claude Tardif, Gregory G Schwartz, et al.
International Journal of Experimental Diabesity Research|May 15, 2003
Development of type 1 diabetes in wild bank voles associated with islet autoantibodies and the novel ljungan virusBo Niklasson, Knud E Heller, Bryan Schønecker, et al.
Journal of the American College of Cardiology|July 25, 2009
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trialAbhiram Prasad, Bernard J Gersh, Michel E Bertrand, et al.
Journal of the American College of Cardiology|February 21, 2004
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trialHitinder S Gurm, A Michael Lincoff, David Lee, et al.
European Heart Journal|September 2, 2015
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trialsJacob A Udell, Marc P Bonaca, Jean-Philippe Collet, et al.
Nature Communications|October 9, 2015
Structure of Ljungan virus provides insight into genome packaging of this picornavirusLing Zhu, Xiangxi Wang, Jingshan Ren, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 18, 2012
Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experienceOlcay Aksoy, E Murat Tuzcu, Stephen G Ellis, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|February 28, 2020
Association of adoption of transradial access for percutaneous coronary intervention in ST elevation myocardial infarction with door-to-balloon timeChetan P Huded, Samir R Kapadia, Jad A Ballout, et al.
The American Surgeon|May 5, 2023
Effects of the COVID-19 Pandemic on the Trauma Population in a Level 1 Trauma CenterJavier A Michael, Morgan E Roberts, Andrew N Haiflich, et al.
Clinical Cardiology|August 25, 2020
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)Calvin C Sheng, Debasis Sahoo, Siddharth Dugar, et al.
Pageof 126